Search research articles
Contact Us
Filters
Showing results (1021-1030 of 1,482) with videos related to
Page
of 149
Sort By:
Cancer
|
August 3, 2021
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis
Abhishek Maiti, Courtney D DiNardo, Wei Qiao, et al.
Blood Cancer Journal
|
April 21, 2022
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
Keith W Pratz, Panayiotis Panayiotidis, Christian Recher, et al.
Blood Advances
|
April 22, 2021
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
Curtis A Lachowiez, Sanam Loghavi, Ken Furudate, et al.
Blood Cancer Journal
|
March 31, 2025
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study
Alex Bataller, Koji Sasaki, Samuel Urrutia, et al.
Blood
|
February 19, 2020
Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors
Dyana T Saenz, Warren Fiskus, Christopher P Mill, et al.
European Journal of Pediatrics
|
October 11, 2023
Acute pharyngitis in children and adults: descriptive comparison of current recommendations from national and international guidelines and future perspectives
Roberta Pellegrino, Edoardo Timitilli, Maria Carmen Verga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2023
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Jayastu Senapati, Warren C Fiskus, Naval Daver, et al.
Blood Cancer Journal
|
June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
Jayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Blood Advances
|
May 27, 2026
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML
Nicholas J Short, Hagop M Kantarjian, Naval G Daver, et al.
Blood
|
April 3, 2025
Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes
Patrick K Reville, Bofei Wang, Jennifer Marvin-Peek, et al.
Page
of 149
Search research articles
Search
Showing results (1021-1030 of 1,482) with videos related to
Sort By:
Page
of 149
Cancer
|
August 3, 2021
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis
Abhishek Maiti, Courtney D DiNardo, Wei Qiao, et al.
Blood Cancer Journal
|
April 21, 2022
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
Keith W Pratz, Panayiotis Panayiotidis, Christian Recher, et al.
Blood Advances
|
April 22, 2021
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
Curtis A Lachowiez, Sanam Loghavi, Ken Furudate, et al.
Blood Cancer Journal
|
March 31, 2025
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study
Alex Bataller, Koji Sasaki, Samuel Urrutia, et al.
Blood
|
February 19, 2020
Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors
Dyana T Saenz, Warren Fiskus, Christopher P Mill, et al.
European Journal of Pediatrics
|
October 11, 2023
Acute pharyngitis in children and adults: descriptive comparison of current recommendations from national and international guidelines and future perspectives
Roberta Pellegrino, Edoardo Timitilli, Maria Carmen Verga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2023
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Jayastu Senapati, Warren C Fiskus, Naval Daver, et al.
Blood Cancer Journal
|
June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
Jayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Blood Advances
|
May 27, 2026
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML
Nicholas J Short, Hagop M Kantarjian, Naval G Daver, et al.
Blood
|
April 3, 2025
Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes
Patrick K Reville, Bofei Wang, Jennifer Marvin-Peek, et al.
Page
of 149